MAR-ALLOPURINOL 100 MG
ALLOPURINOL : 100 MG · DIN 02396327 · MARCAN PHARMACEUTICALS INC
Health Canada status: MARKETED
What is MAR-ALLOPURINOL?
MAR-ALLOPURINOL 100 MG contains ALLOPURINOL : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02396327, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAR-ALLOPURINOL used for?
Treatment of gout; primary/secondary uric acid nephropathy; prophylaxis of urate deposition/renal calculi in malignancies; prevention of recurrent calcium lithiasis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02396327 |
|---|---|
| Brand name | MAR-ALLOPURINOL |
| Generic / active ingredient | ALLOPURINOL : 100 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M04AA01 ALLOPURINOL |
| AHFS class | 92:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Apr-2013 |
| Original market date | 2013-04-17 00:00:00 |
How is it administered?
Oral, after meals. Gout: 100-800 mg/day (max 300 mg per single dose). Secondary hyperuricemia: 600-800 mg/day for 2-3 days. Pediatrics: 10 mg/kg/day. Adjust based on serum uric acid levels.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard practice is 15-30°C, but text refers to Section 11 which is not fully quoted).
How is it supplied?
100 mg: Bottles of 100 and 1000. 200 mg & 300 mg: Bottles of 100 and 500.
Contraindications
Hypersensitivity to allopurinol; breast-feeding women; children (except for secondary hyperuricemia in malignancy or Lesch-Nyhan syndrome).
Warnings and precautions
Discontinue immediately at first sign of rash (risk of SJS/TEN/DRESS). HLA-B*5801 allele carriers at higher risk. May cause drowsiness. Acute gout attacks may be precipitated at start of therapy.
What can be used instead?
Other Canadian products sharing ATC code M04AA01 ALLOPURINOL. 12 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALLOPURINOL-100 | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00555681 |
| ALLOPURINOL-200 | 200 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02130157 |
| ALLOPURINOL-300 | 300 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00555703 |
| APO-ALLOPURINOL TABLETS | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00402818 |
| APO-ALLOPURINOL TABLETS | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 00479799 |
| APO-ALLOPURINOL TABLETS | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 00402796 |
| JAMP ALLOPURINOL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421593 |
| JAMP ALLOPURINOL | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421607 |
| JAMP ALLOPURINOL | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02421615 |
| MAR-ALLOPURINOL | 200 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02396335 |
Who else supplies ALLOPURINOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALLOPURINOL appears in 369 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.